Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, despite the difficult circumstances, because that oh-so-familiar routine of deadlines and Zoom and Skype calls has returned. But what can you do? The world keeps spinning no matter what, however wobbly it may feel. So to cope, try brewing a cup of stimulation. Your neurons can use the help. Meanwhile, here are some tidbits to get you going. Hope your day goes well and stay safe. …

Given that it typically takes years to develop a vaccine, the timetable for the Operation Warp Speed initiative was incredibly ambitious. Under constant pressure from a White House anxious for good news and a public desperate for a silver bullet to end the crisis, The New York Times notes, U.S. government researchers are fearful of political intervention in the coming months and are struggling to ensure that the government maintains the right balance between speed and rigorous regulation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy